First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men-Reference-Cited by-同舟云学术

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men

Published:2022-07 Issue:7 Volume:20 Page:1684-1695
ISSN:1538-7836
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:Journal of Thrombosis and Haemostasis

Author:

Nowotny Bettina^ORCID,Thomas Dirk^ORCID,Schwers Stephan^ORCID,Wiegmann Sara^ORCID,Prange Wolfgang^ORCID,Yassen Ashraf^ORCID,Boxnick Stefanie^ORCID

Funder

Bayer

Publisher

Elsevier BV

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.15744

Reference25 articles.

1. Novel antithrombotic strategies for treatment of venous thromboembolism;Weitz;Blood,2020

2. How effective and safe is factor XI inhibition in preventing venous thrombosis?;Bauer;JAMA,2020

3. Factor XI and contact activation as targets for antithrombotic therapy;Gailani;J Thromb Haemost,2015

4. Factor XI as a therapeutic target;Gailani;Arterioscler Thromb Vasc Biol,2016

5. Factor XI antisense oligonucleotide for venous thrombosis;Buller;N Engl J Med,2015

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the factor XI monoclonal antibody SHR-2004 in healthy subjects;Expert Opinion on Investigational Drugs;2024-08-22

2. Therapeutic Potential of FXI Inhibitors: Hype or Hope?;Drugs;2024-07-29

3. The current landscape of factor XI inhibitors;Thrombosis Update;2024-06

4. The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease;Journal of Thrombosis and Thrombolysis;2024-04-25

5. Factor XI: structure, function and therapeutic inhibition;Journal of Thrombosis and Thrombolysis;2024-04-16